Michelle Hermiston, MD, PhD
Professor
Pediatrics
School of Medicine

Education & Training

Show all (2) Hide

• Diversity, Equity, and Inclusion Champion Training University of California 2019
• Residency Pediatrics University of California, San Francisco

Websites

Show all (2) Hide

• Profile at UCSF Cancer Center (cancer.ucsf.edu)
• Clinical Profile at UCSF Benioff Children's Hospital (ucsfbenioffchildrens.org)

Grants and Projects

Show all (3) Hide

• Improving risk allocation and developing novel therapies for children with T-ALL, NIH, 2015-2021
• Interplay of Innate and Adaptive Immunity in Lupus Pathogenesis, NIH, 2010-2015
• Role of CD45 in Hematopoiesis and Lymphomagenesis, NIH, 2003-2007

Publications (145)

Top publication keywords:
PanniculitisLeukocyte Common AntigensDrug Resistance, NeoplasmReceptors, Interleukin-7Lymphoma, T-CellSEC Translocation ChannelsGlucocorticoidsLymphohistiocytosis, HemophagocyticHistiocytosis, Langerhans-CellReceptors, Antigen, T-CellLeukemia-Lymphoma, Adult T-CellPrecursor T-Cell Lymphoblastic Leukemia-LymphomaPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaInterleukin-7

• Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study.
  Blood advances 2024 Wistinghausen B, Toner K, Barkauskas DA, Jerkins LP, Kinoshita H, Chansky P, Pezzella G, Saguilig L, Hayashi RJ, Abhyankar H, Scull B, Karri V, Tanna J, Hanley P, Hermiston ML, Allen CE, Bollard CM
• MRD at the End of Induction and EFS in T-cell Lymphoblastic Lymphoma: Children's Oncology Group Trial AALL1231.
  Blood 2024 Hayashi RJ, Hermiston ML, Wood BL, Teachey DT, Devidas M, Chen Z, Annett RD, Asselin BL, August K, Cho S, Dunsmore KP, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju A, Lam A, Messinger YH,…
• A roadmap to establishing global oncology as a priority initiative within a National Cancer Institute-designated cancer center.
  Journal of the National Cancer Institute 2024 Van Loon K, Breithaupt L, Ng D, DeBoer RJ, Buckle GC, Bialous S, Hiatt RA, Volberding P, Hermiston ML, Ashworth A
• Old is gold: frontline etoposide for pHLH.
  Blood 2024 Gulati N, Hermiston ML
• Evaluation of Culture Conducive to Academic Success by Gender at a Comprehensive Cancer Center.
  The oncologist 2024 Keenan BP, Sibley A, Zhang L, Westring AF, Velazquez AI, Bank EM, Bergsland EK, Boreta L, Conroy P, Daras M, Hermiston M, Hsu G, Paris PL, Piawah S, Sinha S, Sosa JA, Tsang M, Venook AP, Wong M, Yom …

Show all (140 more) Hide

• Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab.
  Blood advances 2024 Chandrakasan S, Jordan MB, Baker A, Behrens EM, Bhatla D, Chien M, Eckstein OS, Henry MM, Hermiston ML, Hinson A, Leiding JW, Oladapo A, Patel SA, Pednekar P, Ray A, Dávila Saldaña BJ, Sarangi SN, …
• A maelstrom of migrating monocytes drives neurodegeneration.
  Immunity 2023 Coufal NG, Hermiston ML
• Risk Factors and Outcomes for Hematotoxicity Following Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia.
  Blood 2023 Kevin O. McNerney, Vanessa A. Fabrizio, Aimee C. Talleur, Stephanie Si Lim, Alexandra Dreyzin, Christina Baggott, Anant Vatsayan, Jenna Rossoff, Snehit Prabhu, Holly L. Pacenta, Christine L Phillips, …
• Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies.
  Journal for immunotherapy of cancer 2023 Temple WC, Nix MA, Naik A, Izgutdina A, Huang BJ, Wicaksono G, Phojanakong P, Serrano JAC, Young EP, Ramos E, Salangsang F, Steri V, Xirenayi S, Hermiston M, Logan AC, Stieglitz E, Wiita AP
• Pre-and post-HSCT use of TKI therapy for fusion-driven B-ALL: A case series of five pediatric, adolescent and young adult patients.
  Cancer reports (Hoboken, N.J.) 2023 Shumock SS, Temple WC, Marinoff A, Aaronson K, Southworth E, Xirenayi S, Lee AG, Leung SG, Sweet-Cordero EA, Hermiston M, Higham C, Stieglitz E
• Mediport use as an acceptable standard for CAR T cell infusion.
  Frontiers in immunology 2023 Eylon M, Prabhu S, John S, King MJM, Bhatt D, Curran KJ, Erickson C, Karras NA, Phillips CL, Satwani P, Hermiston M, Southworth E, Baumeister SHC, Talano JA, MacMillan ML, Rossoff J, Bonifant CL, …
• Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns.
  EClinicalMedicine 2023 Barsan V, Li Y, Prabhu S, Baggott C, Nguyen K, Pacenta H, Phillips CL, Rossoff J, Stefanski H, Talano JA, Moskop A, Baumeister S, Verneris MR, Myers GD, Karras NA, Cooper S, Qayed M, Hermiston M, …
• Hemophagocytic lymphohistiocytosis and clonally related T-cell malignancies in a pediatric patient.
  Pediatric blood & cancer 2023 Meyer LK, Huang I, Huang BJ, Chung JH, Pawar A, Hermiston ML, Loh ML, Ohgami RS, Ruiz-Cordero R, Bhargava P, Marinoff AE
• Mature B-cell lymphomas in adolescents and young adults.
  EJHaem 2023 El-Mallawany NK, Giulino-Roth L, Burke JM, Hermiston M, Allen CE
• Children's Oncology Group's 2023 blueprint for research: Non-Hodgkin lymphoma.
  Pediatric blood & cancer 2023 El-Mallawany NK, Alexander S, Fluchel M, Hayashi RJ, Lowe EJ, Giulino-Roth L, Wistinghausen B, Hermiston M, Allen CE, COG NHL Committee
• Challenging T-ALL to IL-7Rp dual inhibition.
  Blood 2023 Fries C, Hermiston ML
• HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL.
  Blood advances 2023 McNerney KO, Si Lim SJ, Ishikawa K, Dreyzin A, Vatsayan A, Chen JJ, Baggott C, Prabhu S, Pacenta HL, Philips C, Rossoff J, Stefanski HE, Talano JA, Moskop A, Verneris M, Myers D, Karras NA, Brown P, …
• How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults.
  Blood 2023 Si Lim SJ, Ford JB, Hermiston ML
• How I approach B-lymphoblastic lymphoma in children.
  Pediatric blood & cancer 2023 Devine KJ, Fries C, Hermiston M, Wistinghausen B
• Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia.
  Haematologica 2023 Wayne AS, Huynh V, Hijiya N, Rouce RH, Brown PA, Krueger J, Kitko CL, Ziga ED, Hermiston ML, Richards MK, Baruchel A, Schuberth PC, Rossi J, Zhou L, Goyal L, Jain R, Vezan R, Masouleh BK, Lee DW
• Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium.
  Blood advances 2023 Stefanski HE, Eaton A, Baggott C, Rossoff J, Verneris MR, Prabhu S, Pacenta HL, Phillips CL, Talano JA, Moskop A, Margossian SP, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski…
• Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adults.
  Best practice & research. Clinical haematology 2023 Temple WC, Mueller S, Hermiston ML, Burkhardt B
• Allowing Relationships to Unfold: Consult Reason and Topics Discussed in Initial and Subsequent Palliative Care Visits Among Children Who Died From Relapsed/Refractory Cancer.
  Journal of pediatric hematology/oncology nursing 2023 Root MC, Koo J, Collins G, Penumarthy NL, Hermiston M, Bogetz JF
• Pre-clerkship Teaching and Learning in the Virtual Learning Environment: Lessons Learned and Future Directions.
  Medical science educator 2022 Sewell JL, Joshi M, Thanh C, Apollon C, Austin E, Burke C, Cornes S, Davis JA, Hermiston M
• A Transcriptional Classifier Identifies Pediatric T-Cell Acute Lymphoblastic Leukemias at High Risk for End of Induction Minimal Residual Disease.
  Blood 2022 Lauren K. Meyer, Ritu P. Roy, Petri Pölönen, Abdelrahman Elsayed, Benjamin J. Huang, Shunsuke Kimura, Cristina Delgado-Martin, Tiffaney L. Vincent, Theresa Ryan, Brent L. Wood, Zhiguo Chen, Yu Liu, …
• Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children's Oncology Group (COG) Trial AALL1231.
  Blood 2022 Robert J. Hayashi, Michelle L. Hermiston, David T. Teachey, Meenakshi Devidas, Brent L. Wood, Zhiguo Chen, Robert D Annett, Barbara L Asselin, Keith J August, Steve Y Cho, Kimberly P. Dunsmore, Jason …
• Obesity Associates with Inferior Outcomes and Toxicity in Pediatric and Young Adult Patient with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Commercially Manufactured Tisagenlecleucel.
  Blood 2022 Anthony J Ross, Christina Baggott, Snehit Prabhu, Holly Pacenta, Christine Philips, Jenna Rossoff, Heather E Stefanski, Julie Talano, Amy Moskop, Susanne H.C. Baumeister, Michael R Verneris, Gary …
• Peripheral Blast Count at Apheresis Acts Independent of Disease Burden As a Risk Factor for Survival Following Tisagenlecleucel in Children and Young Adults.
  Blood 2022 Vanessa A. Fabrizio, Kristen Miller, Christina Baggott, Snehit Prabhu, Holly Pacenta, Christine L. Phillips, Jenna Rossoff, Heather E. Stefanski, Julie Talano, Amy Moskop, Susanne H.C. Baumeister, …
• Standard Cytogenetic Risk Stratification Is Not Predictive of CD19 CAR Outcomes and Impact of Disease Burden Varies between Cytogenetic Risk Groups.
  Blood 2022 John C. Molina, Vasant Chinnabhandar, Vanessa A Fabrizio, Michael Kunicki, Holly Pacenta, Jenna Rossoff, Heather E Stefanski, Julie Talano, Amy Moskop, Michael R Verneris, Gary Douglas Myers, Nicole …
• 010 CD72 NANOBODY CAR-T CELLS HAVE POTENT ANTITUMOR EFFICACY IN B CELL MALIGNANCIES.
  Leukemia Research 2022 W. Temple, M. Nix, G. Wicaksono, D. Wang, P. Phojanakong, V. Steri, B. Hann, M. Hermiston, A. Wiita
• 049 A TARGETED GENE EXPRESSION CLASSIFIER IDENTIFIES PEDIATRIC T-ALL PATIENTS AT HIGH RISK FOR END INDUCTION MINIMAL RESIDUAL DISEASE POSITIVITY.
  Leukemia Research 2022 L. Meyer, Ritu P. Roy, B. Huang, S. Kimura, Petri Polonen, C. Delgado-Martin, T. Vincent, T. Ryan, B. Wood, Y. Liu, J. Zhang, C. Mullighan, T. Horton, M. Loh, M. Devidas, E. Raetz, R. Hayashi, S. …
• Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 Schultz LM, Eaton A, Baggott C, Rossoff J, Prabhu S, Keating AK, Krupski C, Pacenta H, Philips CL, Talano JA, Moskop A, Baumeister SHC, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, …
• Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia.
  Blood advances 2022 Moskop A, Pommert L, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston ML, Satwani P, …
• Anatomy of a Consult: How a Multidisciplinary Pediatric Stem Cell Transplant Team Considers Specialty Palliative Care Consultation (GP722).
  Journal of Pain and Symptom Management 2022 Griffin Collins, Hannah Beaman, Alvin Ho, Michelle Hermiston, Harvey Cohen, Elizabeth Dzeng
• International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults.
  Blood 2022 Goyal G, Tazi A, Go RS, Rech KL, Picarsic JL, Vassallo R, Young JR, Cox CW, Van Laar J, Hermiston ML, Cao XX, Makras P, Kaltsas G, Haroche J, Collin M, McClain KL, Diamond EL, Girschikofsky M
• Inhibition of the Sec61 translocon overcomes cytokine-induced glucocorticoid resistance in T-cell acute lymphoblastic leukaemia.
  British journal of haematology 2022 Meyer LK, Delgado-Martin C, Sharp PP, Huang BJ, McMinn D, Vincent TL, Ryan T, Horton TM, Wood BL, Teachey DT, Taunton J, Kirk CJ, Hermiston ML
• Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy.
  Blood advances 2022 Fabrizio VA, Boelens JJ, Mauguen A, Baggott C, Prabhu S, Egeler E, Mavroukakis S, Pacenta H, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA,…
• Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 Teachey DT, Devidas M, Wood BL, Chen Z, Hayashi RJ, Hermiston ML, Annett RD, Archer JH, Asselin BL, August KJ, Cho SY, Dunsmore KP, Fisher BT, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju…
• Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.
  American journal of hematology 2022 Pommert L, Schafer ES, Malvar J, Gossai N, Florendo E, Pulakanti K, Heimbruch K, Stelloh C, Chi YY, Sposto R, Rao S, Huynh VT, Brown P, Chang BH, Colace SI, Hermiston ML, Heym K, Hutchinson RJ, Kaplan…
• A pilot trial of prophylactic defibrotide to prevent serious thrombotic microangiopathy in high-risk pediatric patients.
  Pediatric blood & cancer 2022 Higham CS, Shimano KA, Melton A, Kharbanda S, Chu J, Dara J, Winestone LE, Hermiston ML, Huang JN, Dvorak CC
• Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report.
  Blood advances 2022 Fabrizio VA, Phillips CL, Lane A, Baggott C, Prabhu S, Egeler E, Mavroukakis S, Pacenta H, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, …
• Decreased IL-10 accelerates B-cell leukemia/lymphoma in a mouse model of pediatric lymphoid leukemia.
  Blood advances 2022 Fitch BA, Zhou M, Situ J, Surianarayanan S, Reeves MQ, Hermiston ML, Wiemels JL, Kogan SC
• Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021 Schultz LM, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, …
• Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia.
  Blood 2021 Rossoff J, Baggott C, Prabhu S, Pacenta H, Phillips CL, Stefanski H, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras N, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating …
• Digenic Inheritance: Evidence and Gaps in Hemophagocytic Lymphohistiocytosis.
  Frontiers in immunology 2021 Steen EA, Hermiston ML, Nichols KE, Meyer LK
• Intensification of Chemotherapy Using a Modified BFM Backbone for Children, Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Identifies Highly Chemorefractory Patients Who Benefit from Allogeneic Hematopoietic Stem Cell Transplantation.
  Blood 2021 Paul Harker-Murray, Brent L. Wood, Meenakshi Devidas, Zhiguo Chen, Tal Schechter-Finkelstein, Robert J. Hayashi, Keith J August, Kimberly P. Dunsmore, Michelle L. Hermiston, Terzah M. Horton, Yoav H. …
• Vincristine Sulfate Liposome Injection (VSLI, Marqibo®) in Combination with UK ALL-R3 Induction Chemotherapy for Children, Adolescents and Young Adults with Relapsed Acute Lymphoblastic Leukemia (ALL): A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial.
  Blood 2021 Nirali N. Shah, Eric S Schafer, Kenneth Matthew Heym, Andrew E. Place, Melissa A. Burns, Nathan Gossai, Peter Shaw, Michael J. Burke, Bill H. Chang, Michelle L. Hermiston, Reuven J Schore, Teresa …
• Perceptions of specialty palliative care and its role in pediatric stem cell transplant: A multidisciplinary qualitative study.
  Pediatric blood & cancer 2021 Collins GS, Beaman H, Ho AM, Hermiston ML, Cohen HJ, Dzeng EW
• IFN-γ signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS.
  Blood advances 2021 Lin H, Scull BP, Goldberg BR, Abhyankar HA, Eckstein OE, Zinn DJ, Lubega J, Agrusa J, El Mallawaney N, Gulati N, Forbes L, Chinn I, Chakraborty R, Velasquez J, Goldman J, Bashir D, Lam F, Muscal E, …
• ALL-026: Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion Following Loss of B-Cell Aplasia in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia: HESTER Phase II Study.
  Clinical Lymphoma Myeloma & Leukemia 2021 Michael W. Boyer, Sonali Chaudhury, Kara L. Davis, Timothy Alan Driscoll, Stephan A. Grupp, Michelle Hermiston, Samuel John, Amy K. Keating, Christina Kovacs, G. Doug Myers, Christine L. Phillips, …
• Poster: ALL-026: Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion Following Loss of B-Cell Aplasia in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia: HESTER Phase II Study.
  Clinical Lymphoma Myeloma & Leukemia 2021 Michael W. Boyer, Sonali Chaudhury, Kara L. Davis, Timothy Alan Driscoll, Stephan A. Grupp, Michelle Hermiston, Samuel John, Amy K. Keating, Christina Kovacs, G. Doug Myers, Christine L. Phillips, …
• Subcutaneous panniculitis-like T-cell lymphomas with homozygous inheritance of HAVCR2 mutations in Vietnamese pedigrees.
  Pediatric blood & cancer 2021 Nguyen MC, Nguyen V, Le H, Nguyen DV, Nguyen ML, Hermiston ML, Bui CB, Loh AHP
• Concurrent Subcutaneous Panniculitis-like T-Cell Lymphoma and B-Cell Acute Lymphoblastic Leukemia in 2 Pediatric Patients.
  Journal of pediatric hematology/oncology 2021 Smith GA, Levinson AL, Galvin RT, Lalor LE, McCalmont T, Wang L, Geis MC, Odegaard K, Hupp M, Maguiness S, Turcotte LM, Cordoro KM, Hermiston ML
• Targeted gene expression classifier identifies pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients at high risk for end induction minimal residual disease positivity.
  Journal of Clinical Oncology 2021 Lauren K. Meyer, Ritu Roy, Benjamin J. Huang, Cristina Delgado-Martin, Tiffaney L. Vincent, Brent L. Wood, Yu Liu, Jinghui Zhang, Charles Grenfell Mullighan, Terzah M. Horton, Mignon L. Loh, Meenakshi…
• Fludarabine-exposure predicts disease control following CD19-specific car t cell (tisagenlecleucel); a report from pediatric real-world car consortium.
  Cytotherapy 2021 K.J. Curran, V.A. Fabrizio, A. Mauguen, J.J. Boelens, C. Baggott, S. Prabhu, H. Placenta, C.L. Phillips, J. Rossoff, H. Stefanski, J. Talano, A. Moskop, S.P. Margossian, M.R. Verneris, G. Myers, N.A. …
• T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis.
  Blood 2021 Chaturvedi V, Marsh RA, Zoref-Lorenz A, Owsley E, Chaturvedi V, Nguyen TC, Goldman JR, Henry MM, Greenberg JN, Ladisch S, Hermiston ML, Jeng M, Naqvi A, Allen CE, Wong HR, Jordan MB
• Double trouble for Langerhans cell histiocytosis.
  Blood 2021 Hermiston ML
• 149 Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion Following Loss of B-Cell Aplasia in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia: HESTER Phase II Study.
  2021 Michael W Boyer, Sonali Chaudhury, Kara L Davis, Timothy Alan Driscoll, Stephan Grupp, Michelle Hermiston, Samuel John, Amy K Keating, Christina Kovacs, Andrea Magley, G. Doug Myers, Christine L …
• Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children's Oncology Group (COG) Trial AALL1231.
  Blood 2020 David T. Teachey, Meenakshi Devidas, Brent L Wood, Zhiguo Chen, Robert James Hayashi, Robert D Annett, Barbara L Asselin, Keith J August, Steve Y Cho, Kimberly P. Dunsmore, Brian T. Fisher, Jason L. …
• HESTER: A Phase II Study Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia Experiencing Loss of B-Cell Aplasia.
  Blood 2020 Michael W Boyer, Sonali Chaudhury, Kara L Davis, Timothy Alan Driscoll, Stephan A Grupp, Michelle Hermiston, Samuel John, Amy K Keating, Christina Kovacs, Andrea Magley, Gary Douglas Myers, Christine …
• ZUMA-4: A Phase 1/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients With Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma.
  Blood 2020 Alan S. Wayne, Gerard Michel, Daniel W. Lee, André Baruchel, Sonali Chaudhury, Patrick A. Brown, Michelle Hermiston, Joerg Krueger, Tong Shen, Kristy Tailford, Behzad Kharabi Masouleh
• JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation.
  Blood 2020 Meyer LK, Verbist KC, Albeituni S, Scull BP, Bassett RC, Stroh AN, Tillman H, Allen CE, Hermiston ML, Nichols KE
• Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020 Hayashi RJ, Winter SS, Dunsmore KP, Devidas M, Chen Z, Wood BL, Hermiston ML, Teachey DT, Perkins SL, Miles RR, Raetz EA, Loh ML, Winick NJ, Carroll WL, Hunger SP, Lim MS, Gross TG, Bollard CM
• Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes.
  The Journal of clinical investigation 2020 Meyer LK, Huang BJ, Delgado-Martin C, Roy RP, Hechmer A, Wandler AM, Vincent TL, Fortina P, Olshen AB, Wood BL, Horton TM, Shannon KM, Teachey DT, Hermiston ML
• Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Burke MJ, Kostadinov R, Sposto R, Gore L, Kelley SM, Rabik C, Trepel JB, Lee MJ, Yuno A, Lee S, Bhojwani D, Jeha S, Chang BH, Sulis ML, Hermiston ML, Gaynon P, Huynh V, Verma A, Gardner R, Heym KM, …
• The bone marrow microenvironment as a mediator of chemoresistance in acute lymphoblastic leukemia.
  Cancer drug resistance (Alhambra, Calif.) 2019 Meyer LK, Hermiston ML
• Protein Translocation Inhibitors Overcome Cytokine-Induced Glucocorticoid Resistance in T-Cell Acute Lymphoblastic Leukemia.
  Blood 2019 Lauren K. Meyer, Cristina Delgado-Martin, Phillip P. Sharp, Dustin McMinn, Christopher J. Kirk, Jack Taunton, Michelle L. Hermiston
• Role of Disease Mechanism in Hematopoietic Cell Transplantation Outcomes for Hemophagocytic Lymphohistiocytosis.
  Blood 2019 Aleksandra S. Dain, Michelle L. Hermiston, Kristin A. Shimano, Sandhya Kharbanda, Alexis Melton, Jasmeen Dara, James N Huang, Christopher C. Dvorak
• The Combination of Dexamethasone and Ruxolitinib Synergistically Attenuates Disease Manifestations in a Preclinical Model of Hemophagocytic Lymphohistiocytosis.
  Blood 2019 Lauren K. Meyer, Katherine Verbist, Sabrin Albeituni, Rachel Bassett, Michelle L. Hermiston, Kim E. Nichols
• Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO).
  Pediatric blood & cancer 2019 Jordan MB, Allen CE, Greenberg J, Henry M, Hermiston ML, Kumar A, Hines M, Eckstein O, Ladisch S, Nichols KE, Rodriguez-Galindo C, Wistinghausen B, McClain KL
• CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition.
  PloS one 2019 Meyer LK, Delgado-Martin C, Maude SL, Shannon KM, Teachey DT, Hermiston ML
• Calming the storm in HLH.
  Blood 2019 Zinter MS, Hermiston ML
• The epigenome in pediatric acute lymphoblastic leukemia: drug resistance and therapeutic opportunities.
  Cancer drug resistance (Alhambra, Calif.) 2019 Meyer LK, Hermiston ML
• PS962 PHASE 1 RESULTS OF ZUMA-4: KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN PEDIATRIC AND ADOLESCENT PATIENTS WITH RELAPSED/REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKEMIA.
  HemaSphere 2019 A.S. Wayne, V. Huynh, N. Hijiya, R. Rouce, P.A. Brown, J. Krueger, M. Rytting, C.L. Kitko, E. Dela Ziga, M. Hermiston, M.K. Richards, A. Baruchel, T. Shen, L. Goyal, R. Vezan, R. Jain, D.W. Lee
• Gene expression signature associated with in vitro dexamethasone resistance and post-induction minimal residual disease in pediatric T-cell acute lymphoblastic leukemia.
  Journal of Clinical Oncology 2019 Lauren K. Meyer, Cristina Delgado-Martin, Ritu Roy, Benjamin J. Huang, Tiffaney Vincent, Adam Olshen, Brent L. Wood, Yu Liu, Jinghui Zhang, Charles Grenfell Mullighan, Terzah M. Horton, Mignon L. Loh,…
• Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities.
  British journal of haematology 2019 Burkhardt B, Hermiston ML
• Mechanisms of Glucocorticoid Response and Resistance in Lymphoid Malignancies.
  2019 Lauren K. Meyer, Michelle L. Hermiston
• Children's Oncology Group (COG) AALL0434: Successful Disease Control without Cranial Radiation in Newly Diagnosed T Lymphoblastic Lymphoma (T-LL).
  Blood 2018 Robert James Hayashi, Stuart S. Winter, Kimberly P. Dunsmore, Meenakshi Devidas, Brent Wood, Michelle L. Hermiston, David T Teachey, Sherrie L. Perkins, Rodney R. Miles, Elizabeth A. Raetz, Mignon L. …
• Glucocorticoids Paradoxically Induce Intrinsic Steroid Resistance through a STAT5-Mediated Survival Mechanism in T-Cell Acute Lymphoblastic Leukemia.
  Blood 2018 Lauren K. Meyer, Benjamin Huang, Ritu Roy, Aaron Hechmer, Anica Wandler, Cristina Delgado-Martin, Adam B. Olshen, Terzah M. Horton, David T Teachey, Kevin M. Shannon, Michelle L. Hermiston
• Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model.
  Oncoimmunology 2018 Chu Y, Lee S, Shah T, Yin C, Barth M, Miles RR, Ayello J, Morris E, Harrison L, Van de Ven C, Galardy P, Goldman SC, Lim MS, Hermiston M, McAllister-Lucas LM, Giulino-Roth L, Perkins SL, Cairo MS
• Age-Related Impaired Efficacy of Bone Marrow Cell Therapy for Myocardial Infarction Reflects a Decrease in B Lymphocytes.
  Molecular therapy : the journal of the American Society of Gene Therapy 2018 An S, Wang X, Ruck MA, Rodriguez HJ, Kostyushev DS, Varga M, Luu E, Derakhshandeh R, Suchkov SV, Kogan SC, Hermiston ML, Springer ML
• High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-ALL.
  SLAS discovery : advancing life sciences R & D 2018 Perez DR, Nickl CK, Waller A, Delgado-Martin C, Woods T, Sharma ND, Hermiston ML, Loh ML, Hunger SP, Winter SS, Chigaev A, Edwards B, Sklar LA, Matlawska-Wasowska K
• Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.
  Leukemia 2018 Sun W, Malvar J, Sposto R, Verma A, Wilkes JJ, Dennis R, Heym K, Laetsch TW, Widener M, Rheingold SR, Oesterheld J, Hijiya N, Sulis ML, Huynh V, Place AE, Bittencourt H, Hutchinson R, Messinger Y, …
• Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia.
  Blood 2018 Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM, Carroll WL, Carson R, Dai Y, Devidas M, Dunsmore KP, Fuller T, Glisovic-Aplenc T, Horton TM, Hunger SP, Loh ML, Maude SL, Raetz EA, Winter SS, Grupp …
• Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas.
  Pediatric blood & cancer 2017 Yeh EA, Greenberg J, Abla O, Longoni G, Diamond E, Hermiston M, Tran B, Rodriguez-Galindo C, Allen CE, McClain KL, North American Consortium for Histiocytosis
• Abstract 2642: Preclinical efficacy of daratumumab in acute lymphoblastic leukemia.
  Clinical Research (Excluding Clinical Trials) 2017 Karen Lee Bride, Tiffaney Vincent, Soo-Yeon L. Im, Tori Fuller, Theresa Ryan, David M. Barrett, Shannon L. Maude, Mignon L. Loh, Michelle L. Hermiston, Stephan A. Grupp, Brent L. Wood, David T. …
• Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases.
  Proceedings of the National Academy of Sciences of the United States of America 2017 McNally JP, Millen SH, Chaturvedi V, Lakes N, Terrell CE, Elfers EE, Carroll KR, Hogan SP, Andreassen PR, Kanter J, Allen CE, Henry MM, Greenberg JN, Ladisch S, Hermiston ML, Joyce M, Hildeman DA, …
• JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.
  Leukemia 2017 Delgado-Martin C, Meyer LK, Huang BJ, Shimano KA, Zinter MS, Nguyen JV, Smith GA, Taunton J, Winter SS, Roderick JR, Kelliher MA, Horton TM, Wood BL, Teachey DT, Hermiston ML
• CRLF2 Rearrangement Status in Ph-like ALL Predicts Intrinsic Glucocorticoid Resistance In Vitro that is Reversible with Targeted MAPK and PI3K Pathway Inhibition.
  Blood 2016 Lauren K Meyer, Cristina Delgado-Martin, Shannon L Maude, David T Teachey, Michelle L. Hermiston
• JAK/STAT Pathway Inhibition Reverts IL7-Induced Glucocorticoid Resistance in a Subset of Human T-Cell Acute Lymphoblastic Leukemia.
  Blood 2016 Cristina Delgado-Martin, Kristin Shimano, Matthew S Zinter, Justin T. Wahlstrom, Geoffrey A. Smith, Jack Taunton, Stuart S. Winter, Justine E. Roderick, Michelle Kelliher, Terzah M. Horton, Brent L. …
• Measurement of Phosphorylated ERK As a Prognostic and Predictive Marker for MEK Inhibition in Pediatric B-Lymphoblastic Leukemia: A Pilot Study.
  Blood 2016 Pillai Pallavi Madhusoodhan, Nikki Ann Evensen, Jason Saliba, Ashfiyah Chowdhury, Daniel Newman, Cristina Delgado-Martin, Teena Bhatla, Mignon L. Loh, Michelle L. Hermiston, William L. Carroll
• Mechanism of IL-10 Protective Effect in Development of Childhood B Cell Acute Lymphoblastic Leukemia.
  Blood 2016 Briana Fitch, Michelle L. Hermiston, Joseph L. Wiemels, Scott C. Kogan
• Microrna (miR)-17-92 Contributes to Therapy Resistance in Burkitt Lymphoma Cells.
  Blood 2016 Rodney R. Miles, Vladimir Rodic, Matthew J. Barth, Mitchell S. Cairo, Michelle L. Hermiston
• Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: therapeutic horizons.
  British journal of haematology 2016 Galardy PJ, Bedekovics T, Hermiston ML
• Ibrutinib Alone and in Combination with Dexamethasone and Carfilzomib Significantly Inhibits Cell Proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Ibrutinib May be a Future Targeted Agent in Combination Therapy in Patients with PMBL.
  Blood 2015 Sanghoon Lee, Changhong Yin, Janet Ayello, Erin Morris, Lauren Harrison, Carmella van de Ven, Matthew J. Barth, Rodney R. Miles, Paul J. Galardy, Stanton Goldman, Megan S Lim, Michelle L. Hermiston, …
• Ibrutinib Significantly Prolonged Survival in a Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: Ibrutinib May be a Potential Adjuvant Agent in the Treatment of BL.
  Blood 2015 Sanghoon Lee, Changhong Yin, Janet Ayello, Erin Morris, Timmy O'Connell, Lauren Harrison, Carmella van de Ven, Matthew J. Barth, Rodney R. Miles, Paul J. Galardy, Stanton Goldman, Megan S Lim, …
• Abstract 17412: Paracrine Role of B Lymphocytes in Successful Bone Marrow Cell Therapy for Myocardial Infarction.
  Circulation 2015 Xiaoyin Wang, Hilda J Rodriguez, Melissa A Ruck, Kirstin Aschbacher, Michelle L Hermiston, Matthew L Springer
• MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.
  Blood 2015 Jones CL, Gearheart CM, Fosmire S, Delgado-Martin C, Evensen NA, Bride K, Waanders AJ, Pais F, Wang J, Bhatla T, Bitterman DS, de Rijk SR, Bourgeois W, Dandekar S, Park E, Burleson TM, Madhusoodhan PP…
• Unbiased modifier screen reveals that signal strength determines the regulatory role murine TLR9 plays in autoantibody production.
  Journal of immunology (Baltimore, Md. : 1950) 2015 Mills RE, Lam VC, Tan A, Cresalia N, Oksenberg N, Zikherman J, Anderson M, Weiss A, Hermiston ML
• Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.
  Blood 2015 Maude SL, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Selvanathan A, Ryan T, Hall J, Wood AC, Tasian SK, Hunger SP, Loh ML, Mullighan CG, Wood BL, Hermiston ML, Grupp SA, Lock RB, Teachey DT
• MAPK Signaling Cascades Mediate Distinct Glucocorticoid Resistance Mechanisms in Pediatric B-Precursor ALL.
  Blood 2014 Courtney L Jones, Christy M Gearheart, Susan Fosmire, Cristina Delgado-Martin, Faye Pais, Jinhua Wang, Teena Bhatla, Danielle S Bitterman, Simone R de Rijk, Wallace Bourgeois, Smita C. Dandekar, …
• The CXCR4/CXCL12 Axis Mediates Chemotaxis, Survival, and Chemoresistance in T-Cell Acute Lymphoblastic Leukemia.
  Blood 2014 Angela Liou, Cristina Delgado-Martin, David T. Teachey, Michelle L. Hermiston
• Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia.
  British journal of haematology 2014 Dandekar S, Romanos-Sirakis E, Pais F, Bhatla T, Jones C, Bourgeois W, Hunger SP, Raetz EA, Hermiston ML, Dasgupta R, Morrison DJ, Carroll WL
• A(nother) RAF mutation in LCH.
  Blood 2014 Shannon K, Hermiston M
• Histone Deacetylase Inhibitors Enhance Cell Death In Burkitt Lymphoma Cells By Modulating Expression Of The WNT/ß-Catenin Pathway and Survivin.
  Blood 2013 Faye Pais, Matthew J. Barth, Rodney R. Miles, Michelle L. Hermiston
• Inhibition Of The Wnt Pathway Leads To Improved Chemosensitivity In Pediatric Acute Lymphoblastic Leukemia.
  Blood 2013 Smita C. Dandekar, Eleny Romanos-Sirakis, Faye Pais, Teena Bhatla, Courtney L Jones, Wallace Bourgeois, Stephen P. Hunger, Elizabeth A. Raetz, Michelle L. Hermiston, Ramanuj Dasgupta, Debra J. …
• Transcription Activator-Like Effector Nucleases (TALENs)-Mediated Deletion Of MIR17HG In Burkitt Lymphoma Cells Decreases mTOR Pathway Activity and Increases Chemosensitivity.
  Blood 2013 Faye Pais, Sanghoon Lee, Vladimir Rodic, Matthew J. Barth, Mitchell S. Cairo, Michelle L. Hermiston, Rodney R. Miles
• The structural wedge domain of the receptor-like tyrosine phosphatase CD45 enforces B cell tolerance by regulating substrate specificity.
  Journal of immunology (Baltimore, Md. : 1950) 2013 Zikherman J, Parameswaran R, Hermiston M, Weiss A
• Initially disadvantaged, TEL-AML1 cells expand and initiate leukemia in response to irradiation and cooperating mutations.
  Leukemia 2013 Li M, Jones L, Gaillard C, Binnewies M, Ochoa R, Garcia E, Lam V, Wei G, Yang W, Lobe C, Hermiston M, Passegué E, Kogan SC
• The Order of Exposure to Cytotoxic Chemotherapy and the Proteasome Inhibitor Bortezomib Dictates the Extent of Reversal of Chemotherapy Resistance in T-ALL.
  Blood 2012 May Y. Szeto, Justin Wahlstrom, Michelle L. Hermiston
• Cellular and molecular mechanisms for lupus nephritis in a mouse model of systemic lupus erythematosus (159.4).
  The Journal of Immunology 2012 Si-Han Hai, Viola Lam, Brian Cook, Michelle Hermiston
• The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.
  Nature 2012 Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, Easton J, Chen X, Wang J, Rusch M, Lu C, Chen SC, Wei L, Collins-Underwood JR, Ma J, Roberts KG, Pounds SB, Ulyanov A, Becksfort J, …
• Aberrant MAPK and PI3K Signaling Contribute to Chemotherapy Resistance in T Cell Acute Lymphoblastic Leukemia by Altering the Balance of Apoptosis Mediators,.
  Blood 2011 Justin Wahlstrom, Kristin Ammon, Christopher Esquivel, Jason Law, Michelle L. Hermiston
• Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project.
  Blood 2011 Jinghui Zhang, Li Ding, Linda Holmfeldt, Gang Wu, Susan L. Heatley, Debbie Payne-Turner, John Easton, Xiang Chen, Jianmin Wang, Michael Rusch, Charles Lu, Shann-Ching Chen, Racquel Collins-Underwood, …
• Donor myocardial infarction impairs the therapeutic potential of bone marrow cells by an interleukin-1-mediated inflammatory response.
  Science translational medicine 2011 Wang X, Takagawa J, Lam VC, Haddad DJ, Tobler DL, Mok PY, Zhang Y, Clifford BT, Pinnamaneni K, Saini SA, Su R, Bartel MJ, Sievers RE, Carbone L, Kogan S, Yeghiazarians Y, Hermiston M, Springer ML
• An activating mutation in CD45 generates a novel murine model of hemophagocytic disorders in the context of a MHC Class 1 restricted TCR. (109.11).
  The Journal of Immunology 2011 Rachelle Tibbetts, Viola Lam, Nicole Cresalia, Fleur DeGraaf, Nira Goren, Lawrence Wong, Si-Han Hai, Robyn Mills, Alfonso Roque, Weiss Arthur, Michelle Hermiston
• Impact of TLR9 on hyper-responsive ITAM signaling in a mouse model of SLE (47.24).
  The Journal of Immunology 2011 Robyn Mills, Viola Lam, Diana Tobler, Nir Oksenberg, Nicole Cresalia, Mark Anderson, Jian-Hua Mao, Arthur Weiss, Michelle Hermiston
• Chapter 95 CD45.
  Handbook of Cell Signaling 2010 Michelle L. Hermiston, Vikas Gupta, Arthur Weiss
• Distinct Signaling Profiles and Drug Responses Identify Subpopulations of Pediatric T-Cell Acute Lymphoblastic Leukemia and Lymphoma Patients.
  Blood 2009 Jason Law, Kristin Ammon, Matt Zinter, Jason Wen, Brian Cook, Jonathan M Irish, Michelle L. Hermiston
• PTPN22 deficiency cooperates with the CD45 E613R allele to break tolerance on a non-autoimmune background.
  Journal of immunology (Baltimore, Md. : 1950) 2009 Zikherman J, Hermiston M, Steiner D, Hasegawa K, Chan A, Weiss A
• Requirement for CD45 in fine-tuning mast cell responses mediated by different ligand-receptor systems.
  Cellular signalling 2009 Grochowy G, Hermiston ML, Kuhny M, Weiss A, Huber M
• Oncogenic Kras initiates leukemia in hematopoietic stem cells.
  PLoS biology 2009 Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, Passegué E, Shannon K, Braun BS
• CD45, CD148, and Lyp/Pep: critical phosphatases regulating Src family kinase signaling networks in immune cells.
  Immunological reviews 2009 Hermiston ML, Zikherman J, Zhu JW
• Differential impact of the CD45 juxtamembrane wedge on central and peripheral T cell receptor responses.
  Proceedings of the National Academy of Sciences of the United States of America 2009 Hermiston ML, Zikherman J, Tan AL, Lam VC, Cresalia NM, Oksenberg N, Goren N, Brassat D, Oksenberg JR, Weiss A
• B cells drive lymphocyte activation and expansion in mice with the CD45 wedge mutation and Fas deficiency.
  The Journal of experimental medicine 2008 Gupta VA, Hermiston ML, Cassafer G, Daikh DI, Weiss A
• Langerhans' Cell Histiocytosis.
  Clinical Endocrine Oncology 2008 Matthew F. Gorman, Michelle Hermiston, Katherine K. Matthay
• A Point Mutation in the Juxtamembrane Wedge of CD45 Impacts Myeloid Development and Generates a Novel Model for Hemophagocytic Disorders in the Context of a MHC I-Restricted Transgene.
  Blood 2007 Michelle L. Hermiston, Fleur R. de Graaf, Art Weiss
• The Phenotypic Consequences of an Activating Mutation in the Juxtamembrane Wedge of CD45 Is Sensitive to Genetic Modifiers.
  Blood 2006 Michelle L. Hermiston, Nicole M. Cresalia, Viola Lam, Allison L. Tan, Arthur Weiss
• Epstein-Barr virus-associated B cell lymphoproliferative disease in a child with neonatal-onset multisystem inflammatory disease.
  Arthritis and rheumatism 2006 Modica R, Emery H, Lam W, Hermiston M, Grenert J, Wirt M, von Scheven E
• Dysregulation of signaling pathways in CD45-deficient NK cells leads to differentially regulated cytotoxicity and cytokine production.
  Proceedings of the National Academy of Sciences of the United States of America 2006 Hesslein DG, Takaki R, Hermiston ML, Weiss A, Lanier LL
• The juxtamembrane wedge negatively regulates CD45 function in B cells.
  Immunity 2005 Hermiston ML, Tan AL, Gupta VA, Majeti R, Weiss A
• Chapter 114 CD45.
  Handbook of Cell Signaling 2003 Zheng Xu, Michelle L. Hermiston, Arthur Weiss
• Reciprocal regulation of lymphocyte activation by tyrosine kinases and phosphatases.
  The Journal of clinical investigation 2002 Hermiston ML, Xu Z, Majeti R, Weiss A
• Phenotype of mice lacking functional Deleted in colorectal cancer (Dcc) gene.
  Nature 1997 Fazeli A, Dickinson SL, Hermiston ML, Tighe RV, Steen RG, Small CG, Stoeckli ET, Keino-Masu K, Masu M, Rayburn H, Simons J, Bronson RT, Gordon JI, Tessier-Lavigne M, Weinberg RA
• Forced expression of the tumor suppressor adenomatosis polyposis coli protein induces disordered cell migration in the intestinal epithelium.
  Proceedings of the National Academy of Sciences of the United States of America 1996 Wong MH, Hermiston ML, Syder AJ, Gordon JI
• Forced expression of E-cadherin in the mouse intestinal epithelium slows cell migration and provides evidence for nonautonomous regulation of cell fate in a self-renewing system.
  Genes & development 1996 Hermiston ML, Wong MH, Gordon JI
• Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin.
  Science (New York, N.Y.) 1995 Hermiston ML, Gordon JI
• Organization of the crypt-villus axis and evolution of its stem cell hierarchy during intestinal development.
  The American journal of physiology 1995 Hermiston ML, Gordon JI
• In vivo analysis of cadherin function in the mouse intestinal epithelium: essential roles in adhesion, maintenance of differentiation, and regulation of programmed cell death.
  The Journal of cell biology 1995 Hermiston ML, Gordon JI
• Differentiation and self-renewal in the mouse gastrointestinal epithelium.
  Current opinion in cell biology 1994 Gordon JI, Hermiston ML
• Chimeric-transgenic mice represent a powerful tool for studying how the proliferation and differentiation programs of intestinal epithelial cell lineages are regulated.
  Proceedings of the National Academy of Sciences of the United States of America 1993 Hermiston ML, Green RP, Gordon JI
• Use of transgenic mice to characterize the multipotent intestinal stem cell and to analyze regulation of gene expression in various epithelial cell lineages as a function of their position along the cephalocaudal and crypt-to-villus (or crypt-to-surface epithelial cuff) axes of the gut.
  Seminars in Cell and Developmental Biology 1993 Michelle L. Hermiston, Jeffrey I. Gordon
• Simultaneous localization of six antigens in single sections of transgenic mouse intestine using a combination of light and fluorescence microscopy.
  The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1992 Hermiston ML, Latham CB, Gordon JI, Roth KA
• Use of transgenic mice to infer the biological properties of small intestinal stem cells and to examine the lineage relationships of their descendants.
  Proceedings of the National Academy of Sciences of the United States of America 1991 Roth KA, Hermiston ML, Gordon JI
• Isolation of mutants defective in early steps of meiotic recombination in the yeast Saccharomyces cerevisiae.
  Genetics 1991 Malone RE, Bullard S, Hermiston M, Rieger R, Cool M, Galbraith A